Compare Stocks: KNSA, BNTX, UTHR, and GMAB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$93.09 +1.1%	$91.69	$79.52 ▼ $124.00	$23.54B	1.27	957,443 shs	650,462 shs
GMAB Genmab A/S	$31.94 +1.9%	$27.98	$23.14 ▼ $35.43	$19.92B	0.83	2.17 million shs	3.42 million shs
KNSA Kiniksa Pharmaceuticals International	$76.75 -1.4%	$64.42	$32.89 ▼ $82.94	$5.99B	0.05	710,545 shs	403,456 shs
UTHR United Therapeutics	$499.73 -0.3%	$535.95	$302.19 ▼ $609.35	$21.43B	0.59	518,533 shs	472,927 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	+1.05%	-0.62%	+1.20%	+3.95%	-17.46%
GMAB Genmab A/S	+1.91%	+2.21%	+9.83%	+20.35%	+40.89%
KNSA Kiniksa Pharmaceuticals International	-1.39%	+0.91%	+24.41%	+35.82%	+128.08%
UTHR United Therapeutics	-0.31%	-7.26%	-6.03%	-12.11%	+61.35%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$93.09 +1.1%	$91.69	$79.52 ▼ $124.00	$23.54B	1.27	957,443 shs	650,462 shs
GMAB Genmab A/S	$31.94 +1.9%	$27.98	$23.14 ▼ $35.43	$19.92B	0.83	2.17 million shs	3.42 million shs
KNSA Kiniksa Pharmaceuticals International	$76.75 -1.4%	$64.42	$32.89 ▼ $82.94	$5.99B	0.05	710,545 shs	403,456 shs
UTHR United Therapeutics	$499.73 -0.3%	$535.95	$302.19 ▼ $609.35	$21.43B	0.59	518,533 shs	472,927 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	+1.05%	-0.62%	+1.20%	+3.95%	-17.46%
GMAB Genmab A/S	+1.91%	+2.21%	+9.83%	+20.35%	+40.89%
KNSA Kiniksa Pharmaceuticals International	-1.39%	+0.91%	+24.41%	+35.82%	+128.08%
UTHR United Therapeutics	-0.31%	-7.26%	-6.03%	-12.11%	+61.35%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTX BioNTech	2.74	Moderate Buy	$127.81	37.30% Upside
GMAB Genmab A/S	2.85	Moderate Buy	$39.50	23.67% Upside
KNSA Kiniksa Pharmaceuticals International	2.80	Moderate Buy	$87.38	13.84% Upside
UTHR United Therapeutics	2.85	Moderate Buy	$646.00	29.27% Upside

Current Analyst Ratings Breakdown

Latest KNSA, BNTX, UTHR, and GMAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	KNSA Kiniksa Pharmaceuticals International	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B-) ➝ Hold (C+)
8/11/2026	GMAB Genmab A/S	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
8/7/2026	GMAB Genmab A/S	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$40.00 ➝ $42.00
8/6/2026	UTHR United Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$515.00
8/6/2026	UTHR United Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$704.00 ➝ $677.00
8/5/2026	BNTX BioNTech	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$142.00
8/5/2026	BNTX BioNTech	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$130.00 ➝ $125.00
7/31/2026	UTHR United Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
7/30/2026	KNSA Kiniksa Pharmaceuticals International	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/30/2026	KNSA Kiniksa Pharmaceuticals International	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$75.00 ➝ $90.00
7/29/2026	KNSA Kiniksa Pharmaceuticals International	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)

(Data available from 8/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTX BioNTech	$3.25B	7.25	$1.34 per share	69.73	$81.64 per share	1.14
GMAB Genmab A/S	$3.72B	5.35	$1.61 per share	19.84	$9.55 per share	3.34
KNSA Kiniksa Pharmaceuticals International	$677.56M	8.84	$0.79 per share	96.69	$8.38 per share	9.16
UTHR United Therapeutics	$3.18B	6.73	$32.99 per share	15.15	$149.22 per share	3.35

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTX BioNTech	-$1.29B	-$7.83	N/A	N/A	N/A	-63.54%	-6.86%	-6.00%	11/3/2026 (Estimated)
GMAB Genmab A/S	$963M	$1.27	25.15	19.72	1.90	19.08%	14.89%	7.73%	N/A
KNSA Kiniksa Pharmaceuticals International	$59.01M	$0.97	79.12	37.08	N/A	9.59%	13.65%	10.09%	10/27/2026 (Estimated)
UTHR United Therapeutics	$1.33B	$27.95	17.88	16.84	1.69	41.56%	20.18%	17.98%	N/A

Latest KNSA, BNTX, UTHR, and GMAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	GMAB Genmab A/S	$0.37	$0.54	+$0.17	$0.4910	$1.12 billion	$1.16 billion
8/5/2026	Q2 2026	UTHR United Therapeutics	$6.86	$7.27	+$0.41	$7.27	$804.65 million	$783.30 million
7/28/2026	Q2 2026	KNSA Kiniksa Pharmaceuticals International	$0.2995	$0.30	+$0.0005	$0.30	$226.49 million	$243.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTX BioNTech	N/A	N/A	N/A	N/A	N/A
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A
KNSA Kiniksa Pharmaceuticals International	N/A	N/A	N/A	N/A	N/A
UTHR United Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTX BioNTech	0.01	7.85	7.80
GMAB Genmab A/S	0.81	2.46	2.44
KNSA Kiniksa Pharmaceuticals International	N/A	3.90	3.49
UTHR United Therapeutics	N/A	5.73	5.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTX BioNTech	15.52%
GMAB Genmab A/S	7.07%
KNSA Kiniksa Pharmaceuticals International	53.95%
UTHR United Therapeutics	94.08%

Insider Ownership

Company	Insider Ownership
BNTX BioNTech	19.20%
GMAB Genmab A/S	1.54%
KNSA Kiniksa Pharmaceuticals International	51.98%
UTHR United Therapeutics	8.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTX BioNTech	7,807	252.88 million	204.33 million	Optionable
GMAB Genmab A/S	3,029	623.53 million	613.93 million	Optionable
KNSA Kiniksa Pharmaceuticals International	220	78.02 million	37.47 million	Optionable
UTHR United Therapeutics	1,400	42.89 million	39.20 million	Optionable

KNSA, BNTX, UTHR, and GMAB Headlines

Recent News About These Companies

HC Wainwright Issues Pessimistic Outlook for UTHR Earnings

August 14 at 8:41 AM | marketbeat.com

Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

August 13 at 7:06 PM | marketbeat.com

United Therapeutics’s Q2 earnings call: Our top 5 analyst questions

August 12 at 1:46 PM | msn.com

United Therapeutics (UTHR) Q2 2026 Earnings Call Transcript

August 12 at 1:46 PM | fool.com

Liquidia, An IBD 50 Stock, Tops Sales Views Amid United Therapeutics Rivalry

August 12 at 10:31 AM | investors.com

Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock

August 11, 2026 | insidertrades.com

United Therapeutics (NASDAQ:UTHR) EVP Sells $4,291,515.00 in Stock

August 9, 2026 | americanbankingnews.com

Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $4,928,030.00 in Stock

August 9, 2026 | americanbankingnews.com

Royal Bank Of Canada Cuts United Therapeutics (NASDAQ:UTHR) Price Target to $677.00

August 9, 2026 | americanbankingnews.com

Assenagon Asset Management S.A. Purchases 37,355 Shares of United Therapeutics Corporation $UTHR

August 9, 2026 | marketbeat.com

United Therapeutics (NASDAQ:UTHR) Sees Strong Trading Volume - Should You Buy?

August 7, 2026 | marketbeat.com

United Therapeutics (NASDAQ:UTHR) EVP Paul Mahon Sells 8,300 Shares

August 7, 2026 | insidertrades.com

Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $4,902,570.00 in Stock

August 7, 2026 | americanbankingnews.com

United Therapeutics Corporation $UTHR Shares Sold by Bank of America Corp DE

August 7, 2026 | marketbeat.com

How Investors May Respond To United Therapeutics (UTHR) EPS Strength And Ralinepag’s Phase 3 Milestone

August 6, 2026 | finance.yahoo.com

Paul Mahon Sells 8,300 Shares of United Therapeutics (NASDAQ:UTHR) Stock

August 6, 2026 | marketbeat.com

United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock

August 6, 2026 | marketbeat.com

Buy Rating Reiterated on United Therapeutics as Diversified Pipeline Offsets Near-Term Headwinds; $660 Price Target Maintained

August 6, 2026 | tipranks.com

UTHR Q2 2026 deep dive: Product pipeline developments offset competitive pressures

August 6, 2026 | msn.com

Royal Bank Of Canada Has Lowered Expectations for United Therapeutics (NASDAQ:UTHR) Stock Price

August 6, 2026 | marketbeat.com

United Therapeutics Q2 Earnings Beat Estimates, Revenues Miss Mark

August 6, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KNSA, BNTX, UTHR, and GMAB Company Descriptions

BioNTech NASDAQ:BNTX

$93.09 +0.97 (+1.05%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$92.17 -0.92 (-0.99%)

As of 08/14/2026 07:52 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Genmab A/S NASDAQ:GMAB

$31.94 +0.60 (+1.91%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$31.80 -0.15 (-0.45%)

As of 08/14/2026 07:53 PM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$76.75 -1.08 (-1.39%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$76.72 -0.03 (-0.05%)

As of 08/14/2026 07:34 PM Eastern

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

United Therapeutics NASDAQ:UTHR

$499.73 -1.54 (-0.31%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$499.92 +0.19 (+0.04%)

As of 08/14/2026 07:34 PM Eastern

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KNSA, BNTX, UTHR, and GMAB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KNSA, BNTX, UTHR, and GMAB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KNSA, BNTX, UTHR, and GMAB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KNSA, BNTX, UTHR, and GMAB Company Descriptions

BioNTech NASDAQ:BNTX

Genmab A/S NASDAQ:GMAB

Kiniksa Pharmaceuticals International NASDAQ:KNSA

United Therapeutics NASDAQ:UTHR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KNSA, BNTX, UTHR, and GMAB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KNSA, BNTX, UTHR, and GMAB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KNSA, BNTX, UTHR, and GMAB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KNSA, BNTX, UTHR, and GMAB Company Descriptions

BioNTech NASDAQ:BNTX

Genmab A/S NASDAQ:GMAB

Kiniksa Pharmaceuticals International NASDAQ:KNSA

United Therapeutics NASDAQ:UTHR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools